Pharmacogenetics and inflammatory bowel disease: Progress and prospects

Inflammatory Bowel Diseases

Volumn 10, Issue 2, 2004, Pages 148-158

  Ho, Gwo Tzer ^a   Lees, Charlie ^a   Satsangi, Jack ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Drug therapy; Genetics; Inflammatory bowel disease; Pharmacogenetics

Indexed keywords

AZATHIOPRINE; BALSALAZIDE; CORTICOSTEROID; FC RECEPTOR; GLUCOCORTICOID RECEPTOR; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; NEUTROPHIL CYTOPLASMIC ANTIBODY; OLSALAZINE; SALAZOSULFAPYRIDINE; THIOPURINE METHYLTRANSFERASE; XANTHINE OXIDASE;

ABDOMINAL DISCOMFORT; BONE MARROW DEPRESSION; CYTOTOXICITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; ENTERITIS; ENZYME ACTIVITY; ETHNIC DIFFERENCE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LEUKOPENIA; LYMPHOID CELL; NAUSEA AND VOMITING; NUCLEIC ACID METABOLISM; OPEN READING FRAME; PANCREATITIS; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TOXIC HEPATITIS; TREATMENT OUTCOME; VARIABLE NUMBER OF TANDEM REPEAT;

6-MERCAPTOPURINE; ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; DRUG THERAPY, COMBINATION; FEMALE; FORECASTING; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; METHOTREXATE; PHARMACOGENETICS; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 1542619842     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200403000-00014     Document Type: Review

References (115)

1. Podolsky DK. The future of IBD treatment. J Gastroenterol. 2003;38 Suppl 15:63-66.
2. Rutgeerts P, D'Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769.
3. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-1405.
4. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
5. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-1608.
6. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279:1200-1205.
7. Sachidanandam R, Weissman D, Schmidt SC et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001;409:928-933.
8. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer. 2001;1:99-108.
9. Telenti A, Aubert A, Spertini F. Individualising HIV treatment-pharmacogenetics and immunogenetics. Lancet. 2002;359:722-723.
10. Flexner CW. Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring. Top HIV Med. 2003;11: 40-44.
11. Vogel F. Moderne probleme der humangenetik. Ergebnisse Inneren Medizin und Keinderheilkunde. 1959;12:52-125.
12. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487-491.
13. Evans DAP, Manley KA, McKuisck VA. Genetic control of isoniazid in man. Br Med J 1960;485-491.
14. Spannbrucker N, Eichelbaum M, Steinke B, Dengler HJ. A human genetic defect in the metabolism of sparteine. Verh Dtsch Ges Inn Med. 1978;1125-1127.
15. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet. 1977;584-586.
16. Gonzalez FJ, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988;331:442-446.
17. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet. 1989;45:889-904.
18. Gonzalez FJ, Vilbois F, Hardwick JP et al. Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics. 1988;2: 174-179.
19. Ingelman-Sundberg M, Evans WE. Unravelling the functional genomics of the human CYP2D6 gene locus. Pharmacogenetics. 2001;11:553-554.
20. Evans WE, McLeod HL. Pharmacogenomics - Drug disposition, drug targets and side-effects. N Engl J Med. 2003;538-549.
21. George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol. 1996;91:1711-1714.
22. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med. 1995; 123:132-142.
23. Lamers CB, Griffione G, Van Hogezand R, Veenendaal RA. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scan J Gastroenterology Suppl. 1999;111-15.
24. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short-and long term toxicity. Ann Intern Med. 1989;641-649.
25. Tiede I, Fritz G, Strand S et al. CD-28 dependent Rac 1 activation is the molecular target of azathioprine in primary human CD4 T lymphocytes. J Clin Invest. 2003;111:1133-1145.
26. Alves S, Prata MJ, Ferreira F, Amorim A. Screening of thiopurine S-methyltransferase mutations by horizontal conformation-sensitive gel electrophoresis. Hum Mutat. 2000;15:246-253.
27. Weinshilboum R. Thiopurine Pharmacogenetics: Clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos. 2001;29: 601-605.
28. Otterness DM, Szumlaski CL, Lennard L et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther. 1997;62:60-73.
29. McLeod HL, Krynetski EY, Reilling M.V., Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical revelevance for childhood lymphoblastic leukaemia. Clin Pharmacol Ther. 2000;14: 567-572.
30. Lennard L. The clinical pharmacology of 6-mercaptopurine. Br J Clin Pharmacol. 2003;52:75-87.
31. Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathiopurine and mercaptopurine intolerance. Ann Intern Med. 2003;608-614.
32. Hon YY, Fessing MY, Pui CH, et al. Polymorphisms of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet. 1999;371-376.
33. Krynetski EY, Evans WE. Genetic polymorphisms of the thiopurine S-methyltransferase: Molecular mechanisms and clinical importance. Pharmacology. 2000;136-146.
34. Yan L, Zhang S, Eiff B et al. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin Pharmacol Ther. 2000;68:210-219.
35. Spire-Vayron dlM, Debuysere H, Fazio F et al. Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics. 1999;9:189-198.
36. Colombel JF, Ferrari N, Debuysere H et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000; 118:1025-1030.
37. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia. 2000;14:567-572.
38. Dubinsky MC, Lamothe S, Yang HY et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
39. Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut. 1996;39:401-406.
40. Relling MV, Hancock ML, Rivera GK et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001-2008.
41. Ansari A, Hassan C, Duley J et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:1743-50.
42. Gearry RB, Barclay ML, Burt MJ et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:395-400.
43. Schwab M, Schaffeler E, Marx C et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics. 2002;12:429-436.
44. Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease maintained on low dose Azathioprine. Aliment Pharmacol Ther. 2002;389-398.
45. Black AJ, McLeod HL, Capell HA et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med. 1998;129:716-718.
46. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol. 1983;16:359-363.
47. McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyl transferase in erythrocytes is indicative of activity in leukaemic blasts from children with acute lymphoblastic leukaemia. Blood. 1995;85:1897-1902.
48. Borstrom, B, Erdman G. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukaemia. Am J Pediatr Hematol Oncol. 1993;15: 80-86.
49. Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther. 2000;14: 1009-1014.
50. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut. 2001;48:642-646.
51. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol. 1995;39:456-459.
52. Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ. Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology. 1999;116:1505-1506.
53. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981-987.
54. Lowry PW, Franklin CL, Weaver AL et al. Leucopaenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine or balsalazide. Gut. 2001;48:656-664.
55. Projuansky R, Maxwell M, Johson J, et al. Molecular genotyping predicts complications of 6-mercaptopurine therapy in childhood IBD. Gastroenterology. 1999;116:A800.
56. Kaskas BA, Louis E, Hindorf U et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut. 2003;52:140-142.
57. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994;35: 360-362.
58. Faubion WAJ, Loftus EVJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121: 255-260.
59. Reinisch W, Gasche C, Wyatt J et al. Steroid dependency in Crohn's disease. Lancet. 1995;345:859-Reinisch, W.
60. Carmichael J, Paterson C, Diaz P, Crompton GK, Kay AB, Grant W. Corticosteroid resistance in chronic asthma. Br Med J. 1981;282: 1419-1422.
61. Seki M, Ushiyama C, Seta N et al. Apoptosis of lymphocytes induced by glucocorticoids and relationship to therapeutic efficacy in patients with systemic lupus erythematosus. Arthritis Rheum. 1998;41:823-830.
62. van Schaardenburg D, Valkema R, Djikmans BA et al. Prednisone treatment of elderly-onset rheumatoid arthritis. Disease activity and bone mass in comparison with chloroquine treatment. Arthritis Rheum. 1995; 38:823-830.
63. Farrell RJ, Murphy A, Long A et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology. 2000;118:279-288.
64. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473-1378.
65. Siddiqui A, Kerb R, Weale ME et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 2003;348:1442-1448.
66. Fellay J, Marzolini C, Meaden ER et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002;359: 30-36.
67. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut. 2003;52:759-766.
68. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA. 1987; 84:7735-7738.
69. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol. 1998;161:5733-5744.
70. Satsangi J, Parkes M, Louis E et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet. 1996;14:199-202.
71. Schwab M, Schaeffeler E, Marx C, et al. An association between the C343ST MDR1 gene polymorphism and susceptibility for UC. Gastroenterology. 2003;124:26-33.
72. DeRijk RH, Schaaf M, de Kloet ER. Glucocorticoid receptor variants: clinical implications. J Steroid Biochem Mol Biol. 2002;81:103-122.
73. Honda M, Orii F, Ayabe T, et al. Expression of glucocorticoid receptor beta in lymphocytes of patients woth glucocorticoid-resistant ulcerative colitis. Gastroenterology. 2000;118:859-866.
74. Hamid Q, Wezel SE, Hauk PJ, et al. Increased glucocorticoid receptor b in airway cells of glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 1999;159:1600-1604.
75. Hamilos DL, Leung DY, Muro S, et al. GRbeta expression in nasal polyp inflammatory cells and its relationship to the anti-inflammatory effects of intranasal flucatisone. J Allergy Clin Immunol. 2001;105:782-787.
76. Leung DY, Hamid A, Vottero A, et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med. 1997;186:1567-1574.
77. Hearing SD, Norman M, Probert CS, Haslam N, Dayan CM. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut. 1999;45:382-388.
78. Creed TJ, Norman MR, Probert CS et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther. 2003;18:65-75.
79. Parsi MA, Achkar JP, Richardson S et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology. 2002;123: 707-713.
80. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther. 2003;17:1451-457.
81. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348:601-608.
82. Taylor KD, Plevy SE, Yang H et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology. 2001;120:1347-1355.
83. Esters N, Vermeire S, Joossens S et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol. 2002;97:1458-1462.
84. Louis E, Vermeire S, Rutgeerts P et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol. 2002;37:818-824.
85. Mascheretti S, Hampe J, Kuhbacher T et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J. 1903;2: 127-136.
86. Mascheretti S, Hampe J, Croucher PJ et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics. 2002;12:509-515.
87. Louis E, El Ghoul A, Vermeire S. Dall'ozzo S, Rutgeerts, P., Paintaud G, Belaiche, J., De Vos, M., Van Gossum, A., Colombel, J. F., and Watier H. A polymorphism in IgG Fc receptor gene FCG3A is associated with biological response to infliximab in Crohn's disease. Gastroenterology. 2003;424:29.
88. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754-758.
89. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2003;1:CD003459.
90. Feagan BG, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med. 1995;332:292-297.
91. Lemann M, Zenjari T, Bouhnik Y et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol. 2000;95:1730-1734.
92. Chabner BA, Donehower C, Schilsky RL. Clinical pharmacology of methotrexate. Cancer Treat Rep. 1981;65:51-54.
93. Frosst P, et al. A candidate genetic risk factor vascular disease: a common mutation in methyelenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
94. Ulrich CM, Yasui Y, Storb R et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood. 2001;98: 231-34.
95. Goto Y, et al. A novel single nucleotide polymorphism in the 3′ untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin Cancer Res. 2001;1952-1956.
96. Ricart E, Taylor WR, Loftus EV et al. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. Am J Gastroenterol. 2002;97:1763-1768.
97. Kalow W, Tang BK, Endrenyi I. Hypothesis: comparisons of inter and intra-indivdual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998;283-289.
98. Cardon LR, Abecasis GR. Using haplotype blocks to map human complex trait loci. Trends Genet. 2003;19:135-140.
99. Goldstein DB. Islands of linkage disequilibrium. Nat Genet. 2001;29: 109-11.
100. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. High-resolution haplotype structure in the human genome. Nat Genet. 2001; 29:229-232.
101. Goldstein DB. Pharmacogenetics in the laboratory and the clinic. N Engl J Med. 2003;348:553-556.
102. Couzin J. Genomics: New mapping project splits the community. Science. 2002;1391-1393.
103. Lesage S, Zouali H, Cezard JP et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002;70:845-857.
104. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology. 2002; 122:854-866.
105. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002;123:679-688.
106. Roussomoustakaki M, Satsangi J, Welsh K et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology. 1997;112:1845-1853.
107. Louis E, Michel V, Hugot JP. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares and smoking but not NOD2/CARD15 genotype. Gut. 2003;52:552-557.
108. Staunton JE, Slonim DY, Coller HA. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A. 2001;98:10787-10792.
109. Yeoh J, Ross ME, Shurtlef SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymohoblastic leukaemia by gene expression profiling. Cancer Cell. 2002;1:133-143.
110. Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. JAMA. 2001;286:2211-2214.
111. Golub TP, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531-537.
112. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403:532-535.
113. Liotta LA, Petricoin EF. Molecular profiling of human cancer. Nat Rev Genet. 2000;48-56.
114. Ornstein DK, Gillespie JW, Paweletz CP, et al. Proteomic analysis of laser capture microdissection in human prostate cancer and in vitro prostate cell lines. Electrophoresis. 2000;2235-2242.
115. Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science. 1996;274:998-1001.